Integrating Genomic Information with Tumor-Immune Microenvironment in Triple-Negative Breast Cancer

• Published in: International journal of environmental research and public health Vol. 19; no. 21; p. 13901
• Main Authors: Otohinoyi, David, Kuchi, Aditi, Wu, Jiande, Hicks, Chindo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 26-10-2022; MDPI
• Subjects: Apoptosis; Biomarkers; Breast cancer; Cancer therapies; Chemotherapy; Clinical outcomes; Cytotoxicity; Datasets; Functional analysis; Gene expression; Genes; Genomes; Genomics; Genomics - methods; Humans; Hypotheses; Immunomodulation; Immunotherapy; Medical prognosis; Microenvironments; Mutation; Patients; Phenotype; Phenotypes; Signal transduction; Stem cells; Survival; Triple Negative Breast Neoplasms - genetics; Tumor Microenvironment - genetics; Tumors; somatic mutations; triple-negative breast cancer; immune microenvironment
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph192113901

the development and progression of triple-negative breast cancer (TNBC) is driven by somatic driver mutations and the tumor-immune microenvironment. To date, data on somatic mutations has not been leveraged and integrated with information on the immune microenvironment to elucidate the possible oncogenic interactions and their potential effects on clinical outcomes. Here, we investigated possible oncogenic interactions between somatic mutations and the tumor-immune microenvironment, and their correlation with patient survival in TNBC.
We performed analysis combining data on 7,875 somatic mutated genes with information on 1,751 immune-modulated genes, using gene-expression data as the intermediate phenotype, and correlated the resulting information with survival. We conducted functional analysis to identify immune-modulated molecular networks and signaling pathways enriched for somatic mutations likely to drive clinical outcomes.
We discovered differences in somatic mutation profiles between patients who died and those who survived, and a signature of somatic mutated immune-modulated genes transcriptionally associated with TNBC, predictive of survival. In addition, we discovered immune-modulated molecular networks and signaling pathways enriched for somatic mutations.
The investigation revealed possible oncogenic interactions between somatic mutations and the tumor-immune microenvironment in TNBC, likely to affect clinical outcomes.